Open AccessGlycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine
Author(s) -
ChungYi Wu,
Cheng-Wei Cheng,
Chih-Chuan Kung,
Kuo-Shiang Liao,
Jia-Tsrong Jan,
Che Ma,
ChiHuey Wong
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2119995119
Subject(s) - messenger rna , biology , epitope , virology , cd8 , endoplasmic reticulum , immune system , antibody , major histocompatibility complex , microbiology and biotechnology , gene , immunology , genetics
Significance To contain the spread of SARS-CoV-2, the mRNA vaccine of viral spike protein has proven to be highly effective, although the efficacy against the emerging variants is decreasing. Here, we show that the mRNA of spike protein with deletion of glycosites in the RBD or especially the S2 domain to expose more conserved epitopes can be used as a broadly protective vaccine against the wild type and variants of concern. The spike protein translated from such mRNA was not properly folded, and thus induced cell apoptosis and a strong T cell response. Our findings demonstrate the importance of the glycosylation effect on the development of broadly protective mRNA vaccines.